NDA 206995 · Astrazeneca
Iressa
Gefitinib · Oral · Kinase Inhibitor
OrphanLast checked: Nov 19, 2026Latest source record: May 5, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Jul 13, 2015
Approved uses
1
Original approval plus efficacy supplements
Registered trials
385
71 Phase 3, 6 recruiting
FAERS reports
8,993
8,525 serious, 1,955 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 28, 2023.
IRESSA is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test [see Clinical Studies (14) ] . Limitation of Use: Safety and efficacy of IRESSA have not been established in patients with metastatic NSCLC whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations [see Clinical Studies (14) ] . IRESSA is a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. (1) Limitation of Use: Safety and efficacy of IRESSA have not been established in patients whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations. (1)
Mechanism: The epidermal growth factor receptor (EGFR) is expressed on the cell surface of both normal and cancer cells and plays a role in the processes of cell growth and proliferation. Some EGFR activating mutations (exon 19 deletion or exon 21 point mutation L858R) within NSCLC cells have been identified as contributing to the promotion of tumor cell growth, blocking of apoptosis, increasing the production of angiogenic factors and facilitating the processes of metastasis. Gefitinib reversibly inhibits the kinase activity of wild-type and certain activating mutations of EGFR, preventing...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 13, 2015 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLetterLabelReview
1 products under this application
- IRESSA · GEFITINIB 250MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Gefitinib" as an intervention, any sponsor and status, largest first.
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT04322890 · 6,000 participants (planned) · Start Apr 16, 2020 · Primary completion Dec 24, 2026
Drug: Osimertinib; Alectinib 150 MG and 3 more · For: Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation and 2 more
Sites: Changsha, China
- Iressa vs Best Supportive Care - 2nd/3rd Line Survival StudyPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00242801 · 1,692 participants · Start Jul 2003
Drug: Gefitinib · For: NSCLC
Sites: Capital Federal, Argentina; Bahía Blanca, Argentina; Buenos Aires, Argentina · 211 sites in all
- Iressa Versus Docetaxel (Taxotere)Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00076388 · 1,440 participants · Start Feb 2004 · Primary completion Mar 2007
Drug: Gefitinib; Docetaxel · For: Non-Small-Cell Lung Carcinoma
Sites: Birmingham, Alabama; Fountain Valley, California; Los Angeles, California · 162 sites in all
- First Line IRESSA™ Versus Carboplatin/Paclitaxel in AsiaPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00322452 · 1,329 participants · Start Mar 2006 · Primary completion Apr 2008
Drug: Gefitinib; Carboplatin and 1 more · For: Non-Small Cell Lung Cancer
Sites: Fuzhou, China; Guangzhou, China; Wuhan, China · 56 sites in all
- LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or GefitinibPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT01085136 · 1,154 participants · Start Feb 2010 · Primary completion Oct 2013
Drug: Investigator´s choice of chemotherapy; BIBW 2992 · For: Carcinoma, Non-Small-Cell Lung
Sites: Buenos Aires, Argentina; Kingswood, Australia; South Brisbane, Australia · 97 sites in all
AstraZenecaAstraZeneca (AZN)
NCT01203917 · 1,060 participants · Start Sep 2010 · Primary completion Aug 2012
Drug: Gefitinib · For: Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
Sites: Plovdiv, Bulgaria; Sofia, Bulgaria; Stara Zagora, Bulgaria · 61 sites in all
- Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By SurgeryPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00020709 · 840 participants · Start Jun 2001 · Primary completion Feb 2007
Drug: cisplatin; docetaxel and 2 more · For: Adenocarcinoma of the Lung; Bronchoalveolar Cell Lung Cancer; Large Cell Lung Cancer and 3 more
Sites: San Antonio, Texas
- Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective StudyPivotal-lookingStatus unknown
Tian XieAcademic, hospital or other
NCT04401059 · 744 participants (planned) · Start Nov 9, 2020 · Primary completion Sep 30, 2025
Drug: Elemene plus first or third generation EGFR-TKIs; First or third generation EGFR-TKIs · For: Carcinoma; Non-Small-Cell Lung Cancer; Adenocarcinoma
Sites: Nantong, China; Panjin, China; Shanghai, China · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- malignant neoplasm progression1,824
- drug resistance1,253
- diarrhoea907
- death758
- rash643
- disease progression462
- interstitial lung disease420
- nausea380
- metastases to central nervous system377
- dyspnoea332
- vomiting326
- drug ineffective299
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 801 |
| 2005 | 515 |
| 2006 | 1,182 |
| 2007 | 235 |
| 2008 | 214 |
| 2009 | 194 |
| 2010 | 240 |
| 2011 | 333 |
| 2012 | 87 |
| 2013 | 37 |
| 2014 | 48 |
| 2015 | 239 |
| 2016 | 503 |
| 2017 | 557 |
| 2018 | 614 |
| 2019 | 990 |
| 2020 | 713 |
| 2021 | 430 |
| 2022 | 278 |
| 2023 | 283 |
| 2024 | 249 |
| 2025 | 181 |
| 2026 | 70 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Iressa (Gefitinib)
2024 spending
$1.3M
Beneficiaries
29
198 claims
Per beneficiary
$46,013
$235.13 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $9,962,994 |
| 2021 | $7,349,915 |
| 2022 | $6,625,714 |
| 2023 | $3,529,858 |
| 2024 | $1,334,380 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Mok TS, Wu YL, Thongprasert S, et al. · N Engl J Med 2009 · Clinical Trial, Phase III, Comparative Study
- Cardiovascular adverse events associated with epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: systematic review and network meta-analysis.
Ma Z, Cao F, Liao M, et al. · BMJ 2025 · Network Meta-Analysis, Systematic Review
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
Ramalingam SS, Vansteenkiste J, Planchard D, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Comparative Study
- AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.
Lu S, Dong X, Jian H, et al. · J Clin Oncol 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
Cheng Y, He Y, Li W, et al. · Target Oncol 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer.
Wang XS, Bai YF, Verma V, et al. · J Natl Cancer Inst 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.